Improve the results of phase II trials of thromboprophylaxis with the new oral anticoagulant drugs

Thromb Haemost. 2010 Dec;104(6):1083-4. doi: 10.1160/TH10-09-0584. Epub 2010 Sep 30.
No abstract available

Publication types

  • Comment
  • Editorial

MeSH terms

  • Administration, Oral
  • Anticoagulants / administration & dosage*
  • Anticoagulants / adverse effects
  • Arthroplasty, Replacement, Knee / adverse effects
  • Clinical Trials, Phase II as Topic*
  • Dose-Response Relationship, Drug
  • Elective Surgical Procedures
  • Enoxaparin / administration & dosage
  • Evidence-Based Medicine
  • Factor Xa Inhibitors*
  • Hemorrhage / chemically induced
  • Humans
  • Pulmonary Embolism / blood
  • Pulmonary Embolism / etiology
  • Pulmonary Embolism / prevention & control*
  • Pyrimidinones / administration & dosage
  • Risk Assessment
  • Risk Factors
  • Sulfones / administration & dosage
  • Time Factors
  • Venous Thromboembolism / blood
  • Venous Thromboembolism / etiology
  • Venous Thromboembolism / prevention & control*
  • Venous Thrombosis / blood
  • Venous Thrombosis / etiology
  • Venous Thrombosis / prevention & control*

Substances

  • 1-(1-(3-((6-chloronaphthalen-2-yl)sulfonyl)-2-hydroxypropanoyl)piperidin-4-yl)tetrahydropyrimidin-2(1H)-one
  • Anticoagulants
  • Enoxaparin
  • Factor Xa Inhibitors
  • Pyrimidinones
  • Sulfones